Corgenix, a subsidiary of Corgenix Medical, has signed a five-year contract manufacturing and supply agreement with diaDexus.
As per the agreement, Corgenix will manufacture and supply the PLAC blood test ELISA product for diaDexus.
The PLAC blood test is designed to measure lipoprotein-associated phospholipase A2, a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque.
diaDexus president and chief executive officer Brian Ward said the company is confident that the renewed collaboration with Corgenix will provide it with the necessary manufacturing and support capabilities as it continues to see increased global acceptance of PLAC test.
"We have worked with Corgenix successfully in the past and are confident that this relationship will be a positive step for both companies," Ward added.
